Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Is Eli Lilly stock a buy or a sell after diabetes and obesity treatments easily beat second-quarter sales expectations?

Is Eli Lilly Stock A Buy Or A Sell After Mounjaro And Zepbound Crush Expectations?

Sanofi

Vertex Pharmaceuticals

With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of the most prominent biomedical developers see their stock price rise or fall based on their drug success.

3 Biotech Stocks to Buy on the Dip: August 2024

Eli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.

Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug market

Glp-1 drugs are predicted to become the top-selling pharmaceutical class ever, with projected US sales of $150 billion by 2030. I have written multiple articles on Glp-1 drugs, highlighting their potential impact on the pharmaceutical industry. These drugs are expected to revolutionize the market and generate significant revenue in the coming years.

Incretin Drug Class: Eli Lilly Likely A Big Beneficiary, As Are Many Other Companies

Eli Lilly has sent cease-and-desist letters to US healthcare providers in recent days demanding they stop promoting copycat weight-loss drugs as the supply of the company's drug Zepbound improves, Bloomberg News reported on Wednesday.

Lilly demands doctors stop selling copycat weight-loss drugs, Bloomberg reports

Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.

Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?

The market reacted very positively to Eli Lilly's Q2 earnings report. This isn't the first time the stock has seen a significant run-up in a short period.

Up 10% in 1 Day, Is It Too Late to Buy Eli Lilly Stock?

Biogen

Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.

Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs

Lilly (LLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lilly (LLY) Upgraded to Buy: Here's Why

AbbVie

Pfizer

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.

3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View

Uber

For U.S. stocks, quarterly earnings seasons are set up to follow an old “beat-and-raise” pattern, which can lift share prices. A look ahead at earnings estimates for 2025 highlights a group of companies whose earnings estimates have been raised the most.

Lilly, Uber among the biggest recent winners of the beat-and-raise game in the stock market

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Analysts See Lilly (LLY) as a Buy: Should You Invest?

Netflix

Spotify

A large majority of the companies have already reported second-quarter results. While we can call it a mixed earnings season, there are a few companies that beat expectations and reported record revenue and profits.

3 Stocks on the Rise After Stellar Q2 Earnings Results

Eli Lilly stock (NYSE: LLY) recently reported its Q2 results, with revenues and earnings exceeding the street expectations. The pharmaceutical giant reported sales of $11.3 billion and adjusted earnings of $3.92 per share, compared to the consensus estimates of $9.9 billion and $2.60, respectively.

What's Next For Eli Lilly Stock After A Solid Q2?

Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs New 346,000 square foot facility will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from Lilly Gateway Labs' companies INDIANAPOLIS , Aug. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration and chronic pain. "The opening of LSC expands upon Lilly's long-standing presence in the Boston area," said Daniel Skovronsky, M.D.

Lilly opens state-of-the-art research and development center in the Boston Seaport

Eli Lilly claims that it's finally producing enough of its weight loss drugs. Companies producing substitutes for those drugs may have trouble growing soon.

This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock

Lilly's Mounjaro and Zepbound are only warming up. The company has several other promising drugs in its lineup and pipeline.

Why Eli Lilly Stock's Big Jump Last Week Could Be Just the Beginning of Another Huge Run

As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.

Should Investors Buy Eli Lilly's (LLY) Stock After Strong Q2 Results?

Eli Lilly (LLY) shares finished Monday lower after a back-and-forth session in which an analyst upgrade sent them higher before news of $5 billion in bond sales pulled them into the red.

Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal

Costco

Fund managers have been busy buying amid the ongoing market weakness. Four stocks are near buy points or are building bases.

Funds Load Up On Costco, Eli Lilly, These Other Stocks

Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.

5 ETFs to Make the Most of Eli Lilly's Strength

Eli Lilly and Company reported strong Q2 2024 earnings with revenues up 36% year-on-year, exceeding expectations. Guidance for 2024 was raised by ~$3bn with expectations of $45.4bn — $46.6bn in revenues and EPS of $15.1 — $15.6 on a GAAP basis. Tirzepatide, a key revenue contributor, shows enormous potential in the diabetes and weight loss markets, driving Lilly's share price and market cap valuation.

Eli Lilly Q2 Earnings: Thanks To Tirzepatide, $1 Trillion Valuation Now In Sight

Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

International Markets and Lilly (LLY): A Deep Dive for Investors

Holding a promising future due to recent success in the obesity drug market, Eli Lilly (NYSE:LLY) appears to be bound for continued gains.

Is Eli Lilly a Stock To Buy and Hold Forever?

CarGurus

CleanSpark

Hyatt Hotels

Hillenbrand

Robinhood

PureCycle Technologies

Plug Power

Triumph Group

Trade Desk

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

News for Eli Lilly Stock (LLY)